CIP2A overexpression clinically associates with castration‐resistant prostate cancer (CRPC) [11], and inhibition of both CIP2A and SET inhibits malignant growth of PCa cells [11, 12]. This evidence concerns the gene CIP2A and posterior cortical atrophy.